Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication, and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team, typeset, and proofread approved by the author before publication. We aim to pbost each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
Suggested evaluation of biological drugs role for WHO – Editor’s response / Professor Philip Walson, MD, USA/Germany
Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise? / Armando A Genazzani, DPhil, MD; Nicola Magrini, MD, Italy
Letters to the Editor
WHO leadership in public safety on biosimilars to be commended / Richard O Dolinar, MD, USA
Legislative efforts to limit prescription information sharing between patients and healthcare providers represent a serious threat to the health and safety of the American nation / Janet S Wyatt, RN, PhD, FAANP, USA
Biosimilars naming and prescribing policy in Australia / Brendan Shaw, PhD, Australia
Critical immunogenicity differences will be obscured by a common INN for biosimilars / Edward T Maggio, PhD, USA
Maximizing quality in the manufacture of biologicals / Gustavo Grampp, PhD; Sundar Ramanan, PhD, USA (Biosimilars for Healthcare Professionals)
Biosimilar in clinical and non-clinical safety settings, clinical efficacy trial, pre- and post-marketing monitoring on safety issues / Thijs J Giezen, PharmD, PhD; Sabine MJM Straus, MD, PhD, The Netherlands (Biosimilars for Healthcare Professionals)
Opportunities that Norway sees for the future with the introduction of biosimilar monoclonal antibodies and the hurdles to overcome / Dr Steiner Madsen, Norway (Biosimilars for Healthcare Professionals)
Establishment of reference standards in biosimilar studies / Aijing Zhang, PhD; Associate Professor Jung-Ying Tzeng; Professor Shein-Chung Chow, USA (Biosimilarity and Interchangeability)
Survey about availability and price of medicines in hospitals in European countries / Sabine Vogler, PhD, Austria
Immunogenicity of biosimilar monoclonal antibodies / Vera Brinks, MSc, PhD, The Netherlands
Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries / Sabine Vogler, PhD; Nina Zimmermann, MA; Claudia Habl, Austria
Generic immunosuppressants comparability studies / Marc Maliepaard, PhD; Professor Hubert G M Leufkens, PharmD, PhD, The Netherlands (Generic Immunosuppressants in Transplantation)
The lack of chiral considerations in generics testing / Professor Joseph Gal, USA; Professor Andrew J Hutt, UK
Generic drug policies: overview and global market trends / Helle Håkonsen, MscPharm, PhD; Professor Toverud, Norway
The merits of INN prescribing with a focus on oral molecules: introduction, case histories, how to enhance INN prescribing/reduce confusion / Brian Godman, BSc, PhD, et al. (a total of 10 authors)
Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C / Barbara Milani, Sara Gaspani, Switzerland
Current status with biosimilars: payer’s perspective / Corrine Zara, PharmD, Spain; Brian Godman, BSc, PhD, UK (Biosimilars for Healthcare Professionals)
Perspective on biosimilarity and interchangeability in Canada / Agnes V Klein, MD, Health Canada (Biosimilarity and Interchangeability)
Role of hospital clinical pharmacist in transplantation, generic immunosuppression / Andrea Devaney, UK
European biosimilar monoclonal antibody guidelines: an overview (Biosimilars for Healthcare Professionals)
Comparison of Japan’s biosimilar guidelines with other regulations around the world / Michelle Derbyshire, PhD, GaBI Online Editor (Biosimilars for Healthcare Professionals)
Comparability of biologicals that is arising: discussion and litigation about supplementary protection certificates / John Lisman, The Netherlands (Biosimilars for Healthcare Professionals)
The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead? / Professor Stefan Mühlebach, PhD; Professor Arnold Vulto, PharmD, PhD; Jon SB de Vlieger, PhD; Vera Weinstein, PhD; Beat Flühmann, PhD; Vinod P Shah, PhD, Switzerland (Non-Biological Complex Drugs)
First Asia Pacific Educational Workshop on Non-Biologic Complex Drugs (NBCDs), Kuala Lumpur, Malaysia, 8 October 2013 / Professor Philip Walson, MD; Professor Gerrit Borchard, PharmD, PhD; Professor Jeong Jae Lee, MD; Professor Stefan Mühlebach, PhD; Professor Jacques Rottembourg, MD; Professor Beatriz Silva Lima, PharmD, PhD (Non-Biological Complex Drugs)
Analysis of European policy towards generic medicines / Pieter Dylst, PharmD; Professor Arnold Vulto, PharmD, PhD; Professor Steven Simoens, MSc, PhD (Generic Immunosuppressants in Transplantation)
Assuring Patient Centered Care: Engaging RA Patients in Disease Monitoring and Pharmacovigilance / Janet S Wyatt, PhD, RN, FAANP, USA (Biosimilars for Healthcare Professionals and Non-Biological Complex Drugs)
IAPO breifing paper on biosimilar medicines / Yasemin Dil, UK
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.